Riley Kandel

Frontline zanubrutinib plus rituximab yielded significant efficacy improvements over SOC chemoimmunotherapy for mantle cell lymphoma.

Hagop Kantarjian, MD, discusses the arsenal of TKIs approved for chronic myeloid leukemia and how to navigate them regarding treatment selection.

Christian Grommes, MD, and Ashley Sumrall, MD, FACP, FASCO, discuss the phase 3 IGNITE trial of tirabrutinib in PCNSL.

Experts delineate the biggest presentations they are looking forward to being presented at the 2026 EHA Congress.

First-line zanubrutinib improved real-world treatment duration, time to next treatment, and survival in older chronic lymphocytic leukemia.

Atrial fibrillation was associated with real-world cardiovascular and health care resource utilization burden in CLL/SLL.

Selinexor plus ruxolitinib produced higher SVR35 rates than ruxolitinib alone in JAK inhibitor-naive myelofibrosis.

Tafasitamab plus lenalidomide and R-CHOP showed significant PFS improvements compared with R-CHOP alone in diffuse large B-cell lymphoma.

Mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed or refractory multiple myeloma.

The FDA has published new sets of product-specific guidelines for investigating generic cancer treatments to guide proper evaluation of bioequivalence.

Hematologic oncology experts preview the top ASCO 2026 abstracts to watch in myeloma, MPNs, large B-cell lymphoma, and more.

Brad Haverkos, MD, discusses how he utilizes mogamulizumab for cutaneous T-cell lymphoma and how to manage rashes associated with the treatment.

The FDA granted orphan drug designation to CLN-049 for relapsed or refractory acute myeloid leukemia based on data from early-phase studies.

Suchitra Sundaram, MD, discusses the assortment of therapies available in chronic lymphocytic leukemia and frontline approaches.

Second-line annamycin plus cytarabine injections demonstrated promising responses in patients with relapsed or refractory acute myeloid leukemia.

Ibrutinib monotherapy produced durable efficacy over 10 years in patients with or without TP53-mutated chronic lymphocytic leukemia.

Ashley Sumrall, MD, FACP, FASCO, discusses emerging data for tirabrutinib and the evolving role of CAR T-cell therapy in primary central nervous system lymphoma.

Rituximab following first-line bendamustine demonstrated significant OS and EFS real-world benefits in mantle cell lymphoma.

Luhua (Michael) Wang, MD, discusses the FDA approval of brexu-cel in mantle cell lymphoma and what to know about CAR T-cell therapy in clinical practice.

Iopofosine I 131 produced strong responses in Waldenström macroglobulinemia, according to 12-month folllow-up data from CLOVER WaM requested by the FDA.

Lore Gruenbaum, PhD, discusses the direction mantle cell lymphoma is headed in addition to other critical areas of unmet needs.

Duvelisib demonstrated deep, durable responses and promising efficacy data across peripheral T-cell lymphoma subgroups.

Top experts discuss the most important takeaways and data to come out of this year’s SGO Annual Meeting on Women’s Cancer.

The FDA has granted breakthrough therapy designation to TERN-701 for the treatment of Ph-positive chronic myeloid leukemia in chronic phase.

Stefan K. Barta, MD, MS, discusses the CTCL subtype mycosis fungoides, common adverse effects, and optimal treatment approaches.

Tafasitamab in combination with rituximab and lenalidomide has been approved for relapsed or refractory follicular lymphoma in Australia.

Multipeptide vaccines in combination with BTK inhibitor–based regimens yielded safety and potent T-cell responses in chronic lymphocytic leukemia.

Significantly improved response rates were shown for liso-cel vs real-world data for SOC in later-line relapsed or refractory mantle cell lymphoma.

Lore Gruenbaum, PhD, discusses hot topics in mantle cell lymphoma, such as recently approved CAR T-cell therapies and where she sees the field moving next.

Sagar S. Patel, MD, discusses data from trials evaluating agents in the Orca platform and where they fit into hematologic malignancy treatment paradigms.